Firing Up Glycolysis: BCG Vaccination Effects on Type 1 Diabetes Mellitus

Rinke Stienstra; Mihai G Netea

doi:10.1016/j.tem.2018.10.001

Firing Up Glycolysis: BCG Vaccination Effects on Type 1 Diabetes Mellitus

Trends Endocrinol Metab. 2018 Dec;29(12):813-814. doi: 10.1016/j.tem.2018.10.001. Epub 2018 Oct 13.

Authors

Rinke Stienstra¹, Mihai G Netea²

Affiliations

¹ Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, Wageningen, The Netherlands.
² Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Department for Genomics and Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany. Electronic address: Mihai.Netea@radboudumc.nl.

PMID: 30327169
DOI: 10.1016/j.tem.2018.10.001

Abstract

In addition to the impact of Bacillus Calmette-Guerin (BCG) vaccination on antimicrobial host defence, a novel study reveals beneficial effects on glycaemic control in patients with long-standing type 1 diabetes mellitus (T1DM). These effects are ascribed to an accelerated glucose consumption in immune cells due to increased glycolysis and reduced oxidative phosphorylation.

MeSH terms

Adjuvants, Immunologic / pharmacology*
BCG Vaccine / pharmacology*
Diabetes Mellitus, Type 1 / drug therapy*
Glycolysis / drug effects*
Humans

Substances

Adjuvants, Immunologic
BCG Vaccine